Cambridge Cognition CEO Matthew Stork Excited over potential for growth (Interview)

Cambridge Cognition plc (LON:COG) CEO Matthew Stork joins DirectorsTalk to chat about preliminary results for 2019. Matthew talks us through the highlights, explains why Q1 2020 order intake has been so positive, the impact of COVID-19 and shares his thoughts on the coming months and the future for the company.

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

You might also enjoy reading  Cambridge Cognition Holdings Increase in sales orders of 74% to £8.6 million
Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Cambridge Cognition
Cambridge Cognition CEO Matthew Stork Excited over potential for growth (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions